Physician profile
Ivy Alwell
NPI 1477684009
$5,927.54
in general payments reported to CMS, 2019-2025
26 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical Psychiatric/Mental Health, Adult (Registered Nurse) provider received nationally (typical 2025 total: $121).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,156 · 2022: $1,570 · 2023: $1,864 · 2024: $1,124 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,153 · Education: $48.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,153.29 |
| Education | $48.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,405.98 | 2021-2024 | |
| Supernus Pharmaceuticals, INC. | $755.95 | 2022-2024 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $528.78 | 2021-2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $422.84 | 2021-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $313.40 | 2021-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $301.88 | 2021-2024 | Spravato |
| Lundbeck LLC | $290.13 | 2021-2024 | Rexulti |
| Axsome Therapeutics, INC. | $273.80 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $209.74 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $178.57 | 2021-2023 | Trintellix |
| Corium, LLC | $155.34 | 2021-2024 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $141.84 | 2024-2025 | Cobenfy |
| Eisai INC. | $135.96 | 2021-2022 | |
| Alkermes, INC. | $120.97 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $116.86 | 2021-2024 | Austedo Xr, Uzedy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $111.43 | 2021-2022 | |
| Almatica Pharma LLC | $96.00 | 2021-2024 | Loreev Xr |
| Neurocrine Biosciences, INC. | $82.76 | 2023 | |
| Bausch Health US, LLC | $64.15 | 2021-2024 | Aplenzin |
| Jazz Pharmaceuticals INC. | $53.68 | 2021-2022 | |
| Tris Pharma INC | $45.00 | 2022-2024 | Dyanavel Xr |
| Neos Therapeutics, Lp | $44.81 | 2021 | |
| Noven Therapeutics, LLC | $28.19 | 2021-2024 | Secuado, Xelstrym |
| Indivior INC. | $18.08 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.93 | 2023 | Quviviq |
| Adlon Therapeutics L.P. | $14.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivy Alwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.